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Abstract
Background—Paradoxical tuberculosis (TB)-associated Immune Reconstitution Inflammatory 
Syndrome (IRIS) is a common complication of combination antiretroviral treatment (cART) 
initiation in adults residing in resource-limited regions. Little is known about the burden and 
presentation of TB-IRIS in children initiating cART while receiving TB treatment.
Methods—Prospective cohort study of South African children initiating cART while on TB 
treatment. Children were assessed clinically and by chest x-ray before starting cART and at 2, 4, 
6, and 12 weeks post cART initiation. All children who presented with any signs or symptoms 
suggestive of paradoxical TB-IRIS were classified according to the consensus adult TB-IRIS case 
definition developed by the International Network for Study of HIV-associated IRIS (INSHI) and 
reviewed by an independent expert panel.
Results—In 7 of the 104 children enrolled in the cohort, symptoms and/or clinical or radiological 
signs suggestive of paradoxical TB-IRIS developed after a median of 14 days of cART. In two of 
these cases there was agreement between the INSHI case definition and the expert panel. In an 
additional 3 cases, the INSHI criteria were fulfilled but the expert panel made an alternative 
diagnosis of pneumonia (n=2) and poor adherence to cART (n=1).
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Conclusions—The burden of paradoxical TB-IRIS in children with underlying TB initiating 
cART is low. Including response to antibiotic treatment for pneumonia as a criterion for an 
alternative diagnosis may improve the specificity of the INSHI case definition.
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INTRODUCTION
Immune reconstitution inflammatory syndrome (IRIS) is a complication of combination 
antiretroviral treatment (cART) characterized by clinical deterioration in the first months of 
cART.1 IRIS is believed to be due to rapid restoration of pathogen-specific immune 
responses, resulting in an exuberant inflammatory response to a partially treated infection 
(“paradoxical” IRIS) or progression of a latent or sub-clinical infection (“unmasking” 
IRIS).2 Although several pathogens are associated with IRIS, Mycobacterium tuberculosis 
accounts for nearly half of all IRIS cases.3,4
TB-IRIS in adults has been studied extensively, but little is known about TB-IRIS in 
children.4,5 Extrapolating data from adults to children may be problematic as the 
immunological and pathophysiological response to M. tuberculosis differs between adults 
and children.6 With 1.2 million children expected to receive cART by 2015,7,8 a better 
understanding of pediatric IRIS is important to ensure optimal clinical management of 
children initiating cART.
In the absence of a biomarker, the IRIS diagnosis relies on case definitions. These are 
typically developed by experts and incorporate clinical and laboratory data. To promote 
standardization and comparability of data, the International Network for the Study of HIV-
associated IRIS (INSHI) published consensus case definitions for paradoxical TB-IRIS, 
ART-associated TB, and unmasking TB-IRIS in adults.9 These definitions built upon 
existing IRIS case definitions with three important changes: (1) adaptation of general IRIS 
case definitions to be specific for TB-IRIS; (2) omission of laboratory criteria of response to 
cART (rise in CD4 count, decrease in viral load) for use in resource-limited settings; and (3) 
a three month timeframe for the temporal association with initiation of cART. This INSHI 
definition has been successfully used in the identification of paradoxical TB-IRIS cases 
among adults in two retrospective cohort studies, 10,11 three prospective cohorts, 12-14 and 
three randomized controlled trials. 15-17
We aimed to determine the burden of paradoxical TB-IRIS and evaluate the INSHI 
definition for paradoxical TB-IRIS in a prospective cohort of South African children 
initiating cART while on TB treatment.
METHODS
Study population
The TB HIV IRIS and Nutrition in Kids (THINK) study was a prospective cohort study of 
cART-naive HIV-infected children aged 0 to 8 years initiating cART according to South 
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African treatment guidelines.18,19 Children were enrolled if presenting to the outpatient 
Harriet Shezi Children's HIV Clinic or the Chris Hani Baragwanath Hospital in Soweto, 
South Africa between September 2009 and March 2012.
Participating children had been diagnosed with TB prior to enrollment by their routine care 
provider, based on a combination of clinical signs, contact with an adult with active TB, 
positive tuberculin skin test, suggestive chest X-ray, or positive sputum smear microscopy 
or culture. All diagnostic and treatment decisions were made by the routine care provider in 
accordance with the national guidelines for TB and HIV.20,21 Children generally received 
isoniazid, rifampicin, pyrazinamide, and ethambutol for two months followed by isoniazid 
and rifampicin for four months. Prior to April 2010, initiation of cART in children receiving 
TB treatment was delayed for at least two months and children receiving a cART regimen 
consisting of lopinavir/ritonavir (LPV/r) received additional ritonavir at a 1:1 dosage with 
lopinavir (super-boosted LPV/r).18 Starting in April 2010, initiation of cART was 
recommended 2-4 weeks after starting TB treatment, consisting of super-boosted LPV/r for 
children ≤8 years of age children.19 Children were eligible for study participation 
independent of duration of TB treatment at the start of cART.
Data collection
The THINK study included a pre-cART visit, cART initiation visit, follow-up visits at 2, 4, 
8 and 12 weeks, and visits every three months thereafter until 24 months post cART 
initiation. On the day of cART initiation, the child's health status was assessed by 
questionnaire and physical examination. Children were assessed by a frontal and lateral 
chest x-ray and a tuberculin skin test unless these were performed within two months 
preceding cART initiation. Blood was drawn for CD4 percentage and viral load. During 
follow-up visits, children were assessed for the development of paradoxical TB-IRIS using a 
standardized symptom screen, clinical exam and chest X-ray. The symptom screen inquired 
about new or worsening constitutional, respiratory or abdominal symptoms, new or 
worsening lymph nodes, headaches or drowsiness. A physical exam was performed for signs 
of paradoxical TB-IRIS including enlarged lymph nodes, focal tissue involvement, central 
nervous system involvement, abdominal involvement, presence of serositis, and tuberculin 
hypersensitivity. A chest x-ray was performed at 2, 4, 8 and 12 weeks following cART 
initiation, results were communicated to the clinic clinician. A pediatric radiologist (NM) 
reviewed all chest x-rays using a standardized recording form to classify the evolution on 
chest X-ray findings as improved, stable or worsening.
Classification of initial TB diagnosis
We used the consensus clinical case definitions for pediatric TB to, retrospectively based on 
available data, classify TB as confirmed TB, probable TB, possible TB, unlikely TB and not 
TB.22
Classification of clinical events by expert opinion
An independent panel of 3 South African clinicians experienced in pediatric HIV and TB 
(SM, LF, CV) reviewed the data of all children in whom any clinical event, symptoms or 
signs suggestive of paradoxical IRIS was recorded during the first 3 months of cART. The 
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panel had access to clinical information, laboratory data, chest X-rays, sputum smear 
microscopy and culture results. Study investigators had access to all study documents as 
well as the routine clinic files to answer questions raised by the panel. Experts blinded from 
each other classified each case. In case of disagreement, the classification reached by the 
majority of experts was used.
Classification of clinical events by INSHI criteria
All children presenting with symptoms or signs compatible with paradoxical TB-IRIS were 
classified according to the INSHI criteria. We used the adult criteria because (1) pediatric 
definitions23 have not been validated, (2) viral load monitoring is rarely performed in 
resource limited settings, and (3) it is unclear whether tuberculin skin test or interferon 
gamma release assay (IGRA) conversion as “supportive information” should count as a 
major or minor criterion, making it difficult to use this information. For the adult INSHI 
criteria, a diagnosis of paradoxical TB-IRIS requires (1) a diagnosis of TB that fulfills the 
WHO criteria for diagnosis of TB, (2) an initial response to TB treatment, (3) presence of at 
least one major or two minor clinical criteria, and exclusion of alternative explanations such 
as drug resistant TB, poor adherence, other infections, neoplasm, drug toxicity or drug 
reaction. When alternative explanations cannot be excluded, a case of probable paradoxical 
IRIS is reclassified as paradoxical IRIS if resolution of clinical or radiological findings 
occurs without change in TB or cART treatment (Figure 1). We classified any child with 
definite, probable or possible TB as a case of TB given that there is no strict WHO case 
definition for diagnosis of childhood TB.
Ethics statement
This study was approved by the Institutional Review Boards of the University of North 
Carolina at Chapel Hill and the University of the Witwatersrand, Johannesburg, South 
Africa. All caregivers gave written permission, all children ≥7 years gave assent.
RESULTS
In total, 104 children receiving TB treatment at time of cART initiation were enrolled. At 
baseline, median age was 30 months (IQR: 18-55), 61% were male and 41% were 
malnourished (weight for age z score < −2), median CD4% was 15.5 (IQR 9.7 – 21.7), 
median viral load 310,000 copies/ml (IQR 64,747 - 1,059,113) and median hemoglobin 9.6 
mg/dl (9.0 – 10.8). The median time between start of TB treatment and cART initiation was 
25 days (IQR 15 - 42) (Table 1). During the first 12 weeks of cART, none of the children 
died, 5 were hospitalized, 4 with symptoms or signs compatible with TB-IRIS and one for 
marasmic kwashiorkor.
In 7 (6.7%) of the 104 children, the symptoms or signs compatible with paradoxical TB-
IRIS were recorded during the first 3 months of cART (Tables 2-4). In only two cases were 
the INSHI case definition for paradoxical TB-IRIS fulfilled and the expert panel diagnosed 
TB-IRIS. In 3 children, the INSHI criteria were fulfilled but the expert panel made an 
alternative diagnosis. Two children were classified as not TB-IRIS by both INSHI criteria 
and expert panel.
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Description of two cases classified as TB-IRIS by INSHI criteria and expert panel
An 8-month old child (case 2) started TB treatment based on clinical symptoms, chest X-ray 
suggestive of TB, and a smear positive gastric aspirate. Two months later, at time of cART 
initiation, the child had gained weight but still complained of cough, night sweats, and 
difficulty breathing. Two weeks after cART initiation, the child presented with new weight 
loss and haemoptysis. The chest X-ray showed a new opacification and reticulonodular 
infiltrates. During hospital admission for 8 days, treatment consisted of fluconazole, 
amikacin, piperacillin/tazobactam and nebulization. Four weeks later, without change in TB 
or cART treatment regimen, the chest X-ray improved and symptoms resolved.
Another 8-month old child (case 5) started TB treatment based on clinical symptoms and 
highly suggestive chest X-ray findings of opacification, multiple cavities, right upper lobe 
collapse, and mediastinal nodes with bronchial compression. Radiological symptoms 
initially improved but four weeks after cART initiation, worsening hilar nodes and 
worsening right upper lobe collapse were noted. The child also developed a fever, worsening 
weight loss, and shortness of breath. In hospital, the child received 5 days of ampicillin, 
gentamycin, and oxygen. A chest X-ray 2 months after cART initiation indicated 
improvement under the same TB treatment and cART regimen.
Description of three cases classified as TB-IRIS by INSHI criteria but not by the expert 
panel
Two children (case 6 and 7) were classified as paradoxical TB-IRIS by INSHI criteria but 
the expert panel favored a diagnosis of pneumonia, acknowledging that paradoxical IRIS 
could not be ruled out. Case 6 was a 53-month-old child who had started TB treatment based 
on symptoms, suggestive X-ray and positive smear microscopy. Two weeks later, symptoms 
had resolved and cART was started. One month later, the child presented with night sweats 
and cough. X-ray findings were stable. The child became asymptomatic and remained free 
of symptoms following completion of an ambulatory course of antibiotics. Case 7 was a 30-
month old child who started TB treatment based on symptoms and chest x-ray findings of 
opacification, reticulonodular infiltrate, perihilar streakiness, perihilar nodes and bronchial 
compression. Two weeks after start of TB treatment, symptoms had resolved and cART was 
initiated. Two weeks later, the child presented with fever and respiratory distress. The child 
was hospitalized, responded well to a course of antibiotics and remained symptom free after 
completion of the antibiotics course.
One child (case 3) was classified as paradoxical TB-IRIS by INSHI criteria but the expert 
panel judged non-adherence to cART and HIV progression to be the most likely cause of 
clinical deterioration. The 2-year old boy was diagnosed with TB based on clinical 
symptoms, chest X-ray findings of hilar nodes and collapse of the right middle lobe, and 
splenic micro-abscesses on sonar. At time of cART initiation, the child had improved and 
was asymptomatic. After 2 months of cART, the X-ray showed worsening of hilar nodes 
and middle lobe collapse. CD4 count had increased from 7.9 to 16.6%. Viral load had risen 
sharply, from 63,000 to 400,000 copies/ml. One month later, under the same ambulatory TB 
treatment and cART regimen, the X-ray showed substantial improvement. While meeting 
INSHI criteria, the expert panel incorrectly decided that the viral load increase on cART 
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indicated poor adherence and excluded a diagnosis of TB-IRIS. A later interview revealed 
that the mother stopped administering cART because she was worried about the clinical 
deterioration. This highlights the complexity of interpreting temporality of events, especially 
when reviews are performed by independent experts who may not have access to all 
qualitative details and case stories.
Description of two cases classified as not TB-IRIS by INSHI criteria and expert panel
A 10-month old child (case 1) showed radiological improvement on TB treatment prior to 
cART initiation despite continued presence of night sweats. Two weeks after starting cART, 
the child presented with weight loss. Chest x-ray was stable. As such, only 1 minor clinical 
criterion was present and the child did not fulfill the INSHI criteria for a TB-IRIS diagnosis. 
A 6-year old child (case 4) had culture confirmed TB. He continued to lose weight after 2.5 
weeks of TB treatment, when cART was initiated. As such, the antecedent criterion of 
improved or stabilized condition on TB treatment was not met. Two weeks later, the child 
continued to lose weight and developed breathing difficulties. Upon investigation, the 
mother reported that she had misunderstood instructions and had stopped TB treatment 
when starting cART.
DISCUSSION
The occurrence of paradoxical TB-IRIS complicates the management of individuals 
initiating cART because its clinical presentation can resemble that of another infection, drug 
toxicity, non-adherence with HIV disease progression, or infection with drug-resistant 
tuberculosis. In this prospective cohort study, we observed a relatively low burden of 
paradoxical TB-IRIS in children initiating cART, with 5/104 (4.8%) children meeting the 
INSHI criteria and 2/104 (1.9%) children diagnosed with paradoxical TB-IRIS according to 
an expert panel.
In adult populations, paradoxical TB-IRIS develops typically after a median of 14 to 22 days 
and the most common clinical criteria are new or increasing lymphadenopathy and onset of 
fever.10-12,14,15,17 The lower incidence in children could be due to the fact that a proportion 
of the children diagnosed clinically may not have TB and are thus not be at risk of 
developing paradoxical TB-IRIS. Furthermore, the paucibacilly nature of TB in children 
may result in a lower risk of paradoxical TB-IRIS as the pathogen load is a risk factor for 
TB-IRIS.
Adults who develop paradoxical TB-IRIS are more likely to present with severe 
immunosuppression (median CD4 count range 26 to 64 cells/mm3),10,11,14-17 have 
extrapulmonary TB,12,14,15 and initiate cART after a shorter duration of TB 
treatment.11,15,17 Knowledge of paradoxical TB-IRIS in children is limited to the 
publication of 6 cases. Narendran et al described a severely immunosuppressed (CD4 count 
51 cells/mm3) 12-year-old Indian boy with smear positive pulmonary TB who developed 
fever and mediastinal nodes three days after starting cART.24 Rabie at al described a 3-year-
old severely immunosuppressed (CD4 count 4 cells/mm3) South African boy with 
pulmonary, abdominal and pericardial TB who developed fever, chylous ascites and 
chylothorax 11 days after cART initiation.25 Zampoli et al described 4 cases of paradoxical 
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TB-IRIS.26 Children were between 3 months and 8 years of age, had a diagnosis of 
pulmonary (n=2) or disseminated TB (pulmonary plus abdominal, n=2), a baseline CD4 
count ranging between 16 and 744, and started cART 6 days to 3 months after the start of 
TB treatment. Symptoms or signs of paradoxical TB consisted of worsening respiratory 
symptoms with radiological deterioration (n=2), development of ascites (n=1) and 
worsening axillary lymph nodes and cold abscess. Similar to the six previously reported 
pediatric cases and experience in adults, paradoxical TB-IRIS developed soon (median 15 
days, range 14- 60 days) after initiation of cART.24-27 In contrast to the reported pediatric 
and adult cases, only 1 child in our cohort who developed paradoxical TB (according to 
INSHI criteria) had severe immunodeficiency (CD4% <15) and extrapulmonary TB.
Agreement between the expert panel and INSHI consensus case definition was low, with 
discordance in three cases and only 2 of the 5 cases fulfilling the INSHI case definition 
being classified as cases of paradoxical TB-IRIS by the expert panel. In one case an 
alternative diagnosis of non-adherence to cART was made based on an increase in viral load 
on cART. In two cases, the clinical deterioration was attributed to pneumonia. It is 
interesting to note that spontaneous resolution of disease under the IRIS case definition 
proposed by French et al. includes the phrase “without specific antimicrobial therapy”, 
which would have tipped the diagnosis away from paradoxical TB-IRIS in the two cases 
presenting with pneumonia.28 The low rate of agreement observed in our study highlights 
the difficulty in diagnosing paradoxical TB-IRIS in children in the absence of a biomarker. 
Two adult studies have attempted to validate the INSHI case definition and found relatively 
high agreement. Manosuthi et al. compared the INSHI case definitions to the non-TB 
specific IRIS definition proposed by French et al (which formed the basis for the 
development of the INSHI definition), and found that 18 of 20 cases fulfilled both the 
French and INSHI definition.12,28 Haddow et al compared the INSHI classification to the 
opinion of an expert panel, and found that 13 of the 18 cases identified by experts fulfilled 
the INSHI criteria.13
While this is the first prospective cohort study of paradoxical TB-IRIS in children, several 
limitations should be noted. First, common to many studies of pediatric TB, most children 
did not have confirmation of TB. Misclassification of TB status may have resulted in an 
underestimation of the true burden of paradoxical TB-IRIS. Second, we evaluated the adult 
instead of the pediatric INSHI case definition,23 because the pediatric definition has not 
been validated and uses evidence of virologic response to cART, tuberculin skin test 
conversion, or 5-fold increase in IGRA as supportive observations. While inclusion of 
virologic response may have correctly classified one of the cases (case 4), viral load is rarely 
available soon after start cART. The observation that paradoxical TB-IRIS often occurs in 
the first two weeks after start cART thus complicates the use of virologic response. 
Similarly, the use of tuberculin skin test or IGRA conversion at time of IRIS is not practical 
in most settings.
Conclusion
In this prospective study using standardized clinical and radiological assessment for 
pediatric paradoxical TB-IRIS, we observed a low burden of IRIS, with only 5 children of 
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104 children fulfilling the INSHI consensus case definition for paradoxical TB-IRIS. The 
validity of the adult INSHI criteria for diagnosis of paradoxical TB-IRIS in children is 
suboptimal, with only 2 children classified as paradoxical TB-IRIS by both the INSHI 
criteria and the expert panel. Including response to antibiotic treatment for lower respiratory 
tract infection as a criterion for an alternative diagnosis may improve the specificity to the 
INSHI case definition.
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Diagnostic criteria for paradoxical TB-IRIS established by the International Network for the 
Study of HIV-associated IRIS (INSHI) 9.
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Table 1
Characteristics of 104 children receiving treatment for TB at time of initiation of combination antiretroviral 
treatment
N or median % or IQR
Age (months) 30 18.7 - 53.9
Male sex 63 60.6
Weight for age z-score ≤ −2 43 41.4
Time between TB treatment and start cART (days) 25 15 - 42
Baseline CD4%
a 15.5 9.7 - 21.7
Baseline viral load
b 310,000 64,437 - 1,059,113
Baseline hemoglobin
c 9.6 9.0 - 10.8
a
CD4 % not available for 1 child with paradoxical TB-IRIS
b
Viral load not available for 11 children
c
Hemoglobin not available for 3 children
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